Familial Mediterranean Fever in Iran: A Report from

FMF Registration Center by صالح زاده, فرهاد
Research Article
Familial Mediterranean Fever in Iran: A Report from
FMF Registration Center
Farhad Salehzadeh
Pediatric Department, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS),
No. 105 Shahrak Azadi Azarbyjan Street, Ardabil 56157, Iran
Correspondence should be addressed to Farhad Salehzadeh; salehzadeh f@yahoo.com
Received 10 June 2015; Revised 14 August 2015; Accepted 18 August 2015
Academic Editor: Ruben Burgos-Vargas
Copyright © 2015 Farhad Salehzadeh. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Familial Mediterranean fever (FMF) is a periodic AR autoinflammatory disorder.This comprehensive study describes
FMF in Iran as a country near Mediterranean area.Materials and Methods. From the country FMF registration center 403 patients
according to Tel-Hashomer criteria enrolled this study, 239 patients had MEFV gene mutations analyses. Data, if needed, was
analyzed by SPSS v20. Results. 175 patients (43.4%) were female and 228 patients (56.6%) were male. The mean age was 21.3 years.
Abdominal pain was in 93.3% patients and 88.1% had fever. Abdominal pain was the main complaint of patients in (49.6%). The
mean interval between attacks was 36.5±29.6 days and the mean duration of every episodes was 43.3±34.5 hours. 15.1% of patients
had positive family history and 12.7% had previous surgery; in 52.3% of patients delay in diagnosis was more than three years. 12
commonMEFVgenemutationswere analyzed, 21.33%werewithoutmutations, 39.7%had compound heterozygote, 25.52% showed
heterozygous, and 13.38% showed homozygous results. The most common compound genotype was M694V-V726A (% 10.46) and
in alleles M694V (% 20.9) and V726A (% 12.7) were the most frequent mutations, respectively. Conclusion. M694V was the most
commonmutation, and the most common compound genotype wasM694V-V726A. Our genotype results are similar to Arabs and
in some way to Armenians, erysipelas-like skin lesions are not common in this area, and clinical criteria are the preferred methods
in diagnosis of FMF.
1. Introduction
Familial Mediterranean fever (FMF) is an autosomal reces-
sive inherited disorder [1, 2]. It is common among Mediter-
ranean populations (Jews, Arabs, Turks, and Armenians) [3].
FMF is characterized by recurrent fever and inflammation of
serousmembranes, leading to abdominal pain, joint pain, and
chest pain.
The most important complication of FMF is amyloidosis,
which eventually leads to kidney failure [4]. Symptoms of the
disease usually occur during the first decade of life in more
than 80%of patients [5].The highest prevalence of the disease
among the “Sephardic Jews” and the Armenians has been
reported [6].
FMF seems to be more common in males with the
prevalence rate 1.5 to 2 times [7]. The disease frequency at an
early age and infants is low [8]. In Middle East its prevalence
is one in 2,000 to one in 100, according to different studies
[9].
MEFV gene, responsible for the disease, located on
chromosome 16 P (13.3) codes synthesis of a protein called
pyrin [10].
Ongoing and recurrent inflammation leads to amyloid
production and deposition of it in vital organs, especially the
kidneys [7].
More than 300 known mutations in the MEFV gene have
been reported [11].
The appearance of homozygous mutations was signif-
icantly associated with severe clinical presentations of the
FMF [10, 12]. This mutation is related to disease onset at an
early age and more prevalence of arthritis and progression to
amyloidosis [13].
M680I is common among Armenians and Turks and
is associated with more severe form of the relapsing fever
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in early childhood which may be the only presentation of
familial Mediterranean fever [2]. In 90% of the patients
disease is begun before 20 years of age [9].
Approximately 50% of patients experience joint pain
during the attacks. The pain is usually limited to one joint
at a time [9]. Typical FMF arthritis is usually benign and
self-limited acute monoarthritis [14]. The most commonly
involved joints include hip, knees, elbows, and wrists [14–16].
Protracted febrilemyalgia syndrome (PFMS) is presented
with prolonged fever and an increase of ESR and leukocytosis.
It usually takes 6 to 8 weeks and respond to treatment with
prednisolone [17, 18].TheM694Vmutation associated with a
higher incidence of PFMS [19].
About 45% of patients have experienced pleural attacks.
Pleural attacks are sudden, unilateral attacks that subsides
within 48 hours [20].
Pleuritis prevalence has been between 20% and 80% in
different studies [7]. Pericarditis and tamponade, myocardi-
tis, and cardiac amyloidosis are the most common cardiovas-
cular presentation in FMF [21, 22].
The nonamyloidosis renal involvement has been reported
in 22% of patients and include temporary or perma-
nent hematuria, proteinuria, acute pyelonephritis, interstitial
nephritis, and glomerulonephritis due to coexisting disease
[23, 24].
The classic skin lesion is periodic erysipelas-like skin rash.
It is a pathognomonic finding in FMF which usually fades
within 72–48 hours; fever and leukocytosis may accompany
the rash. The incidence of rash is 3%–46% and is usually
associated with M694V mutation [15]; sometimes erysipelas
rash and fever are the only sign of FMF [25].
Acute scrotal swelling, a painful inflammation of the
testis, in a small percentage of children with FMF, has been
reported. In Arabs it has been described as a common
feature of FMF [26]. Infertility in patients with FMF has no
difference with the general population [27, 28]. Recurrent
aseptic meningitis can rarely occur in FMF; these attacks are
prevented after treatment with colchicine [29].
Familial Mediterranean fever may be associated with
different systemic inflammatory diseases including Behcet,
polyarteritis nodosa and Henoch-Schonlein purpura [30],
spondyloarthropathy [2], multiple sclerosis [31, 32], and
inflammatory bowel diseases [33, 34].
On the basis of clinical findings Tel-Hashomer criteria
have been described to be FMF diagnosis [11, 35].
There is no specific standard laboratory test for FMF;
nowadays compound MEFV gene mutations in hemo- or
heterozygote forms confirm the diagnosis of FMF [36].
2. Materials and Methods
This is a case series study. This study included all patients
with familial Mediterranean fever in FMF Clinic at
Bouali Hospital and FMF Registration Center in Iran
(http://www.fmfiran.ir/). 422 patients were enrolled in this
study; all patients had FMF according to Tel-Hashomer
criteria and/or at least twoMEFV gene mutations. 19 patients
were excluded because of unavailability and study was
conducted on 403 patients with FMF. CommonMEFV genes
Table 1: Clinical findings in our patients.
Clinical symptoms Number of patients Percent
Abdominal pain 376 93.3
Fever 355 88.1
Fatigue 282 70
Anorexia 258 64
Nausea 139 34.5
Myalgia 118 29.3
Vomiting 107 26.6
Arthralgia 103 25.6
Constipation 96 23.8
Chest Pain 72 17.9
Diarrhea 69 17.1
Vertigo 42 10.4
Dysuria 41 10.2
Headache 36 8.9
Arthritis 31 7.7
mutations (E148Q, P369S, F479L, M680I (G/C), M680I
(G/A), I692del, M694V, M694I, K695R, V726A, A744S,
and R761H) have been analyzed in 239 patient. Descriptive
analysis was used to analyze data by V20 SPSS.
3. Results
Themean age of patientswas 21.03 years.The youngest patient
was 1.5 years old and the oldest one was 76 years old. The
average age of onset of symptoms was 9.75 years and the first
decade of life was the most common age range which was in
128 patients (31.8%).
228 patients (56.6%) were males and 333 patients were
living in urban area. The main complaint of patients was
abdominal pain, in 200 cases (49.6%), and abdominal pain
plus fever in 67 (16.6%) patients was the second main
complaint. Table 1 shows the main symptoms of patients.
Interval between attacks was 36.5 ± 29.6 days and the
mean duration of each episode was 43.3 ± 34.5 hours.
239 patients had MEFV gene mutations analysis; Table 2
shows these results. 51 patients (21.33%) had no mutations in
this analysis.
The most common homozygous mutation was M694V-
M694V (7.1%) and compound heterozygous mutation was
M694V-V726A (10.46%) and monoheterozygous mutation
was E148Q (8.7%).
Genotype-phenotype correlation has been shown in
Table 3.
With regard to the time between onset of symptoms and
diagnosis of FMF in 207 patients (52.3%) this period was
more than 3 years.
Colchicine administration in 89.9% patients had good
results and in 7.2% patients showed moderate response while
2.9% patients had poor response. 13.2% of patients used
drug irregularly.Themost common colchicine side effect was
diarrhea in 4.7% of patients.
In our series two cases had erysipelas-like skin rash with
negativeMEFV resultswhich indicate the rarity of this feature
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Table 2: Results of MEFV genes mutations and different allele’s
analysis.
Mutation Genotype Percent Number
Heterozygote
𝑁 = 61 (25.52%)
E148Q 8.7 21
M694V 8.36 20
V726A 2.5 6
A744S 1.7 4
M680I 2.1 5
P396S 1.2 3
R761H 0.84 2
Homozygote
𝑁 = 32 (13.38%)
M694V-M694V 7.1 17
M680I-M680I 2.92 7
E148Q-E148Q 0.84 2
M694I-M694I 0.84 2
V726A-V726A 0.84 2
P396S-P396S 0.42 1
R761H-R761H 0.42 1
Compound
heterozygote
𝑁 = 95 (39.7%)
M694V-V726A 10.46 25
E148Q-M694V 2.96 7
M680I-V726A 6.27 15
R761H-M694V 2.5 6
M680I-M694V 2.5 6
R761H-E148Q 0.42 1
V726A-R761H 2.5 6
M694V-M694I 0.84 2
M680I-R761H 2.5 6
M680I-E148Q 0.84 2
E148Q-P396S 2.96 7
A744S-R761H 0.42 1
E148Q-V726A 1.69 4
K694R-V726A 0.42 1
E148Q-A744S 0.42 1
E148Q-M694I 1.27 3
M694I-M680I 0.42 1
F497L-E148Q 0.42 1
Patient with no
identified mutation
𝑁 = 51 (21.33%)
21.33 50
in this area.We had two siblings with idiopathic hepatitis and
massive ascites who were homozygous for M694V gene.
4. Discussion
Many studies have shown male preponderance in FMF [38,
40, 41]. In Sackesen et al. [52] and Dunder et al. [37] the
average age of onsetwas seconddecade of life. InYilmaz study
[38] 90% of patients had fever, 95% of patients had abdominal
pain, and 19% of patients had erroneous appendectomy. In a
study on 229 patients, 115 were females and 68% of patients
hadMEFV genemutations. High fever in 94% of patients and
abdominal pain in 83% were the main symptoms [53].
Table 3: Genotype and phenotype correlations.
Common
combined
mutations
The most
common alleles
Abdominal pain
𝑁 = 120
V726A-M694V
𝑁 = 159 (12.5%)
M694V
𝑁 = 47 (19.6%)
Fever
𝑁 = 36
V726A-M680I
𝑁 = 5 (13.9%)
M694V
𝑁 = 14 (19.4%)
Chest pain
𝑁 = 12
V726A-M694V
and
R761H-M694V
𝑁 = 2 (16.7%)
M694V
𝑁 = 7 (29.2%)
Joint pain
𝑁 = 6
M694V-M694V
𝑁 = 2 (33.3%)
M694V
𝑁 = 6 (50%)
Patients with
positive family
history
𝑁 = 38
V726A-M694V
𝑁 = 10 (26.3%)
M694V
𝑁 = 25 (32.9%)
Age at FMF onset
1 to 10 years
𝑁 = 156
M694V-M694V
𝑁 = 11 (7.1%)
M694V
𝑁 = 58 (18.1%)
Age at FMF onset
10 to 20 years
𝑁 = 41
V726A-M694V
𝑁 = 5 (12.2%)
M694V
𝑁 = 19 (23.2%)
Age at FMF onset
after 20 years
𝑁 = 42
V726A-M694V
𝑁 = 10 (23.8%)
M694V
𝑁 = 25 (29.8%)
Male
𝑁 = 134
V726A-M694V
𝑁 = 17 (12.7%)
M694V
𝑁 = 49 (18.3%)
Female
𝑁 = 106
M694V-M694V
𝑁 = 11 (10.4%)
M694V
𝑁 = 52 (24.5%)
In Ebrahimi-Fakhari et al. [54] fever in 78% of patients,
peritonitis symptoms in 95%, pleuritis in 59%, arthritis in
32%, arthralgia in 60%, erysipelas-like skin rash in 23%,
vasculitis in 8% have been reported.
In Dundar’s [37] report 49.6% of patients had no MEFV
mutations, 26.41% were heterozygous, 15.29% were com-
pound, and 8.60% were homozygous mutation. In Balci et al.
[55], Esmaeili et al. [41], and Bonyadi et al. [40] case series
results have been shown in Table 4. Comparison of this study
with different ethnic groups has been presented in Table 5.
The genetic expression of this study is similar to Arabs
and somewhat to Armenians.
In this study, the common combined heterozygous muta-
tion was M694V-V726A with 10.46%, M694V-M694V with
7.1%, and M680I-V726A with 6.27%. The most common
genotype of patients was M694V-M694V in different studies
[38, 40, 41]; this genotype was in second rate of our results.
In this study M694V mutation with 18.3% and com-
pound mutation V726A-M694V with 12.7% were common
mutations in male, while M694V mutation with 24.5% and
M694V-M694V with 10.7% were the common genotype
in female. The sexual genotype difference has not been
mentioned in certain studies.
Raremutationswere observed in this study such asK695R
and F479L with 0.2% frequency. In Manna et al. report [53]
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Table 4: Comparison of different genotypes studies.
Studies Mutations frequencies (%)
M694V V726A M680I M694I E148Q
Dundar et al. [37] 68.14 76.4 62.7 0.46 15.5
Yilmaz et al. [38] 55 3 16 0 10
Ben-Chetrit et al. [39] 38 4 8 0 4
Bonyadi et al. [40] 42.4 17 15.2 2.2 16.2
Esmaeili et al. [41] 28 9 7 1 7
Our study 20.9 12.7 10.3 2.1 10.7
Table 5: Comparison of different ethnics’ studies.
Ethnic groups M694V V726A M680I M694I E148Q
Jews [39, 42, 43] 77 12.3 0.6 0 10.2
Armenians [44, 45] 52 26 20 0.2 1.8
Arabs [46–48] 42.5 23.1 9.6 14.1 10.7
Turks [49–51] 71.3 8.5 15 1.7 3.5
Iranian, Azeri Turks [41] 54 16.7 12.6 2.5 14.2
Our study 20.9 12.7 10.3 2.1 10.7
rare mutations were K695R with 0.67%, M694I with 1.04%,
and R761H with 1.91%. In Yilmaz study [38] the R761S in 1%
and V726A in 3% of patients were rare mutations.
The Bonyadi study [56] showed these rare mutations:
A744S in 0.5%, M694I in 2.2%, F479L in 1.3%, P369S in 1.3%,
E167D in 1.2%, and R408Q in 1.2%.
In our study there was one case of amyloidosis who
presented with resistant nephrotic syndrome and M694I-
M694I mutations.
Some studies have shown that the M694V mutation is
associated with a severe form of the disease [55]. Kincir
et al. showed that arthritis and abdominal pain accompany
mutations M694V and E148Q [57].
This study showed that M694V-M694V mutations are
more common in patients with presentation during first
decade of life, while in those with disease presentation
during second decade or later genotype V726A-M694V was
common. Patients with homozygous mutation M694V have
lower age at onset [16].
In our study two patients presented with the complaint
of recurrent orchitis and compound heterozygous mutations
M694V-V726A and M694V-E148Q, and two female siblings
had massive ascites, abdominal pain, and idiopathic hepatitis
with homozygousmutationM697V; this association has been
reported in the literature [2].
5. Conclusion
This study showed that first decade of life is themost common
age in disease presentation of FMF; abdominal pain is the
main symptom; M694V and M694V-V726A are the most
common alleles and compound genotype. M694V-M694V
genotype is associated with lower age presentation and joint
involvement. Our genotype is similar to Arabs and in some
way Armenians and erysipelas-like skin rash is not common
feature in our patients.
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